U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT07507058) titled 'Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma' on March 15.
Brief Summary: This study aims to evaluate the safety and efficacy of hypofractionated radiotherapy in patients with postoperative intermediate-risk head and neck squamous cell carcinoma.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Head and Neck Squamous Cell Carcinoma
Intervention:
RADIATION: Hypofractionated Radiotherapy
Hypofractionated radiotherapy: 45 Gy in 15 fractions (3.0 Gy/fraction) to PGTVtb/PGTVnd-tb and 40.5 Gy in 15 fractions (2.7 Gy/fraction) to PTV1, once daily, 5 days per ...